Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Non Operating Income (2016 - 2025)

Adma Biologics (ADMA) has disclosed Non Operating Income for 13 consecutive years, with -$8.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 138.01% year-over-year to -$8.6 million, compared with a TTM value of -$8.8 million through Dec 2025, up 33.78%, and an annual FY2025 reading of -$8.8 million, up 33.78% over the prior year.
  • Non Operating Income was -$8.6 million for Q4 2025 at Adma Biologics, down from $2.6 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $2.6 million in Q3 2025 and bottomed at -$49.7 million in Q4 2023.
  • Average Non Operating Income over 5 years is -$5.8 million, with a median of -$3.3 million recorded in 2021.
  • The sharpest move saw Non Operating Income tumbled 26016.78% in 2024, then skyrocketed 188.96% in 2025.
  • Year by year, Non Operating Income stood at -$13.2 million in 2021, then surged by 96.67% to -$439058.0 in 2022, then plummeted by 11216.27% to -$49.7 million in 2023, then soared by 92.73% to -$3.6 million in 2024, then plummeted by 138.01% to -$8.6 million in 2025.
  • Business Quant data shows Non Operating Income for ADMA at -$8.6 million in Q4 2025, $2.6 million in Q3 2025, and -$2.7 million in Q2 2025.